Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.
Introduction
Primary brain tumors are a diverse group of neoplasms arising from different cell types of the central nervous system (CNS) . The most common primary brain tumors are (anaplastic) astrocytomas, glioblastomas, meningiomas and other mesenchymal tumors.
The treatment of primary brain tumors requires an interdisciplinary team-work. Complete or near-complete tumor resection without serious sequelae could be provided in many cases.
External beam radiation therapy plays a central role in the primary or adjuvant treatment of primary brain tumors independently from histology. It has shown its effect in increasing the local tumor control (LC) and in overall survival (OS) . Different techniques aim to provide the best available selectivity in dose delivery e.g. 3D-conformal radiotherapy (RT), intensitymodulated radiotherapy (IMRT), fractionated stereotactic radiotherapy (FSRT), or radiosurgery. Charged particle therapy with protons or carbon ions shows benefits over the best photon techniques due to its unique physical and biological properties. Dose deposition with its maximum occurs at the end of the track in the so called Bragg peak. The range of the peaks is shifted to generate an appropriately sized treatment field, the so called spread-out Bragg peak.
The normal tissue thereafter can be spared with its steep dose fall-off behind the target volume.
Particles with high linear energy transfer provide a higher relative biological effectiveness (RBE) because they cause a dense ionization in the target volume.
Chemotherapy (ChT) as radiosensitizing agent can be combined with RT (simultaneously or adjuvant) aiming to increase LC and OS rates. For example, concomitant to RT and adjuvant temozolomide (TMZ) became a part of the standard therapy in primary high grade glial brain tumors.
However no clinical evidence could be drawn for rare CNS tumor entities, for special age groups such as elderly or young patients, and for the emerging radiation modalities, which require a clinical establishment in the frame of randomized clinical investigations.
Meninigiomas are the most common primary non-glial brain tumors in adults and account for 15-30% of all intracranial neoplasms. Despite their generally benign character, they are often neighboring or infiltrating critical neurovascular structures and their growth can cause neurological or neurocognitive deficits leading to a significant worsening in quality of life.
Gross total resection (GTR) provides long-term recurrence-free survival in many cases. If only subtotal resection (STR) can be achieved and for recurrent meningiomas, or in cases of grade II tumors, adjuvant RT should be considered. In cases of anaplastic meningiomas RT should be 3 always a part of the therapy. Due to improvements in treatment planning and technical application of high precision photon RT, FSRT and IMRT have been well established. These techniques showed convincing LC (75-100%) and very low side effect rates.
Glioblastoma multiforme (GBM) is a malignant primary glial brain tumor and it accounts 12-15% of all intracranial neoplasms in adults. GBM is associated with a median OS of only 15 months among patients treated with at least surgical resection and radiotherapy. Age is a significant risk factor for GBM, and the incidence of GBM is increasing along with the aging of the general population. Although survival rates have been improving in the recent years, likely a result of the increased use of TMZ concomitant to post-operative RT and/or as adjuvant therapy.
Embryonal tumor with abundant neuropils and true rosettes (ETANTR) (according to the new world health organization (WHO) classification of primary CNS tumor reclassified as embryonal tumor with multilayered rosettes [ETMR]) is characterized histologically with the presence of undifferentiated neuroepithelial cells, broad bands of well-differentiated neuropil islands, ependymoblastic rosettes and C19MC gene amplification. It is a rare and highly malignant variant of embryonal brain tumors. It usually affects infants and young children under the age of 4 years and exhibits a very aggressive course with a dismal prognosis. Neurocytoma (NC) accounts for only 0.1-0.5 % of all brain neoplasms, displays a slow and benign clinical course with a low recurrence rate and a low tendency to spread. It has the properties of bipotential precursor cells, which can exhibit both glial and neuronal differentiation. It develops mainly in young adults around the third decade of life. GTR ensures high progression-free survival (PFS) and OS rates without recurrence. On the basis of the histological findings, such as nuclear atypia, anaplasia, vascular endothelial proliferation, focal necrosis, and/or an increased mitotic index a subgroup of this tumor entity is defined as atypical NC. An MIB-1 labeling index (MIB-1 LI) of ≥2 % or >3 % has been claimed to be associated with a significantly poorer survival and to correlate with a higher risk of relapse; moreover an MIB-1 LI of >4 % correlates significantly with an unfavorable clinical course. Such a high proliferation index is quite uncommon and is extremely rare at the time of the diagnosis. 
Aims
The aim of this thesis was to seek for strategies resulting in improved therapeutic index for different types of primary CNS tumors.
2.1. The purpose of the assessment of volumetric changes of different grade of meningiomas after treatment with different RBE irradiation was to evaluate the dynamics of tumor response due to different radiation qualities and techniques. We compared the tumor volume (TV) reduction effect of the different radiation qualities, i.e.: photons, protons and carbon ions retrospectively, assessed by the analysis of serial follow-up magnetic resonance imaging (MRI) on patients diagnosed with different grade of meningioma.
2.2. We aimed to evaluate the tolerance and effectivity of the combined treatment approach in elderly patients to define the clinical benefit and the applicability of the Stupp protocol in this special group of patients with GBM. We conducted a retrospective analysis of patients, over 60 years of age diagnosed with GBM who completed a complex treatment of neurosurgery, adjuvant radio(chemo)therapy (RChT) and adjuvant ChT in order to define how this combined treatment is tolerated, and whether it is beneficial in this ageing group, and to search for prognostic factors for quality of life and overall survival.
2.3. In the lack of evidence based approach, we performed a wide literature search on two tumor rarities in the CNS (i.e. ETMR and NC) in order to provide the best treatment options.
2.3.1. Our aim was to introduce a novel complex therapeutic approach for childhood ETMR to improve the therapeutic index using novel technical possibilities. We applied with long-term success in case of recurrence STR, RT of the craniospinal axis (CSI) followed with tumor bed boost with concomitant ChT followed by modified metronomic ChT.
2.3.2. We evaluated different treatment options derived from the literature evaluation in the course of aggressive NC with the purpose to provide useful suggestions on effective management of this rare disease. We investigated the role of CSI, repeated irradiation in the case of recurrence and combination of RT with ChT in the management of atypical central NC. 
Patients and methods
3.1. Volumetric response of intracranial meningioma after photon or particle irradiation.
The date of two groups of 77 patients were analyzed and compared retrospectively who were suffering from inoperable (even biopsy was not feasible; grade of meningioma is unknown), residual or recurrent meningioma, treated in two time periods with different RT modalities.
Group A consists of 38 patients who were treated at the Heidelberg Ion-Beam Therapy Center Male to female ratio was 11:28. Meningiomas were located at the skull base in 25/39, at the convexity in 5/39, in the cavernous sinus in 4/39, at the falx in 2/39, on the optic nerve in 2/39 or at the craniocervical junction in 1/39 patients. IMRT or FSRT was applied with a median dose of 56 Gy (range 39.6-60 Gy) in 1.8 or 2 Gy daily fractions. Patients were individually affixed with special head masks. For delineation of organs at risk and gross tumor volume (GTV) a trimodal image fusion of a contrast-enhanced computed tomography (CT) scan with 3mm slices, a T1 weighted, contrast-enhanced MRI and a DOTATOC-positron emission tomography was used. For photon and proton RT the clinical target volume (CTV) included the GTV as well and a safety margin depending on histology was added (1-3mm in cases of low grade pathology and 10-20mm in atypical and anaplastic tumors). Anatomical borders were 6 respected. According to the MARCIE trial, a 5mm safety margin was given to the GTV for the carbon ion boost RT. For all patients the planning target volume (PTV) was calculated with an additional margin of 2-3mm in Thermoplast-or 1-2mm in Scotch Cast masks-setup.
The first-and second-year follow-up MRIs were compared with the pre-therapeutic one in each patient to evaluate the volumetric tumor response for this study. Therefore, the GTV was delineated on the initial pre-therapeutic MRI as well as on the first-and second-year follow-up MRIs using Siemens Dosimetrist (Siemens Medical Solutions, Concord, CA). Afterwards, these three GTVs (pretherapeutic, first-and second-year follow-up) were compared and TV were calculated in cm 3 (Masterplan Oncentra, Nucletron, Columbia, MD). The statistical analysis was performed with SPSS 20. Paired and two samples t-tests as well as ANOVA tests were done. which was followed with an autologous stem cell transplantation (SCT). 2.5 year later a local recurrence occurred and a reoperation with STR was carried out. Thereafter, she received CSI, with 32 Gy in 1.6 Gy daily fractions followed by RChT comprising tumor bed boost with 24 Gy in 1.6 Gy daily fractions and a residual tumor boost with 6 Gy in 1.5 Gy daily fraction 8 supplemented with 75 mg/m 2 TMZ daily. Modified adjuvant systemic therapy was continued according to the Kieran schema (thalidomide, celecoxib, fenofibrate, etoposid and cyclophosphamid was changed to TMZ) for 1.5 year. She is still tumor-free 6 years after the tumor recurrence without major neurocognitive deficits. This individual approach was evaluated in a broad literature review and with long follow-up, to give advice for optimal treatment strategy in this rare primary brain tumor. 
Post

Volumetric response of intracranial meningioma after photon or particle irradiation.
In Group A, 27 patients were treated by proton RT. The mean initial TV was Vmean= 26.1 ± 22.2 cm 3 . There was a significant absolute TV shrinkage after one year (Vmean=23.5 ± 19.8 cm 3 ; Vchange mean=3.7 ± 4.6 cm 3 , p=0.001). At the two-year follow-up a steady state could be observed compared to the volumes after one year (Vmean=24.3 ± 20.7 cm 3 ). Eleven patients were treated by carbon ion boost combined with IMRT. The mean initial TV was Vmean=26.5 ± 15.4 cm 3 . There was a significant absolute TV shrinkage at one-year follow-up (Vmean=20.9± 14.4 cm 3 ; Vchange mean=5.7 ± 5.6 cm 3 , p=0.011). At two-year follow-up the contrast enhancing volume had decreased (Vmean=12.9 ± 10.0 cm 3 ), however, this shrinkage was not significant (p=0.083). There was no significant difference in TV changes between combined IMRT plus carbon ion boost and proton-treated patients.
In Group B, 16 patients were treated by IMRT. The mean initial TV was Vmean=37.3 ± 29.5 cm 3 . There was a significant absolute TV shrinkage both after one year (Vmean=34.6 ± 28.0 cm 3 ; Vchange mean=4.3 ± 4.1 cm 3 , p=0.003) and at the two-year follow-up (Vmean=23.5 ± 17.5 cm 3 ; Vchange mean=9.0 ± 5.2 cm 3 , p=0.017). There was a significant absolute shrinkage after two years compared to the one-year follow-up as well (Vchange mean=3.4 ± 1.5 cm 3 , p=0.020). Twenty-three patients were treated by FSRT. The mean initial TV was Vmean=26.7 ± 23.1 cm 3 . There was a significant absolute TV shrinkage both after one year (Vmean=20.5 ± 14.3 cm 3 ; Vchange mean=7.0±14.7cm 3 , p=0.042) and at the two-year follow-up (Vmean=13.9 ± 10.0 cm 3 ; Vchange mean=4.7±3.9cm 3 , p=0.001). There was a significant absolute shrinkage at two-year compared to one-year follow-up as well (Vchange mean=1.3 ± 1.8 cm 3 , p=0.038).
There was no significant difference in TV changes between IMRT and FSRT treated patients.
A significant absolute TV shrinkage was found in male as well as in female patients. In men (20/77) the mean initial TV was Vmean=40.6 ± 31.4 cm 3 , after one year Vmean=34.0 ± 27.4 cm 3 (p=0.018) and after two years Vmean=19.5 ± 13.2 cm 3 (p<0.0001). In women (57/77) the mean initial TV was Vmean=24.5 ± 18.4 cm 3 , at one-year follow-up Vmean=21.6 ± 16.4 cm 3 (p<0.001) and two-year follow-up Vmean=17.5 ± 16.2 cm 3 (p<0.0001). Men showed a significant higher shrinkage after irradiation over every modalities and at both follow-up examinations. In male patients the Vchange mean was 10.1 ± 15.8 cm 3 and 7.8 ± 4.6 cm 3 after one and two years, respectively. In women it was Vchange mean=3.5 ± 4.3 cm 3 and 3.9 ± 3.3 cm 3 (Mann-Whitney U-test p=0.028, p=0.022). Therefore, gender was found to be an independent predictive factor for TV change.
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In patients with grade III meningioma (5/77, initial Vmean=31.4 ± 21.5 cm 3 ) we observed significantly higher relative TV shrinkage in comparison to patients with unknown histology (22/77, initial Vmean=22.2 ± 15.1 cm 3 ) as well as to patients with grade I meningiomas (33/77, initial Vmean=30.0 ± 25.1 cm 3 ), both at one-year (p=0.045 and p=0.038) and two-year followup (p=0.010 and p=0.012). The mean relative size of the residual, contrast enhancing TV was 58.0 ± 22.9% and 52.1 ± 13.5% in the grade III cases after one and two years. In patients with unknown histology the residual TV was 89.6 ± 19.9% and 81.7 ± 6.6% as well as 89.3 ± 17.3% and 83.0 ± 13.6% in grade I meningiomas, respectively. Patients with grade II meningioma showed a higher tumor shrinkage at one-and two-year follow-up than patients with unknown or with grade I meningioma, but less tumor volume reduction than grade III. No significance could be detected between the group of grade II meningioma in comparison with the unknown or grade I and grade III tumors.
Neither age, radiation modality (photon vs. charged particle), initial TV, nor operability were found to be significant independent predictive factors for volumetric response at the two-year follow-up. For the total study population (n=75), mean OS was 12.9 months and median OS was 10.3 months [95% confidence interval (CI), 8.9-11.7]. Median PFS was 4.1 months (95% CI, 3.9-9.3). The 6-month and 12-month OS rates were 73.3% and 42.6%, respectively, with a 2-year OS rate of 6.7%. Median OS was 4.2 months among patients who received concomitant ChT only and 13.8 months among those who received both concomitant and adjuvant ChT. The use and duration of adjuvant TMZ were highly significant prognostic factors of longer OS. Median 11 OS times were significantly longer among patients who received adjuvant TMZ versus the median OS time (4.2 months) associated with concomitant therapy only. Median OS after RT was 6.5 months. Biopsy only compared with GTR and KPS <70 were significant negative prognostic factors of OS in both univariate and multivariate analyses. Patients who underwent biopsy with no subsequent partial or total resection had a median OS (4.5 months) that was more than 50% shorter than that of the total study population (10.3 months). Univariate analysis further suggested that additional surgery in patients who experienced disease progression was a significant predictor of longer OS (median OS, 17 vs. 9.2 months for those without salvage surgery, p =0.049). Survival analyses by age suggested no major differences in OS between age groups. The median OS was 10.5 months for patients aged <70 years and 7.7 months for those aged ≥70 years; however, this difference was not statistically significant in univariate analysis (p=0.467). In contrast, age ≥70 years was a negative prognostic factor of PFS in univariate analysis (p=0.0008). The only other negative prognostic factor for PFS was the type of surgery.
As for OS, biopsy only (versus total resection) was a negative prognostic factor for PFS in univariate analysis (p<0.0001). Other factors, including gender, KPS, and tumor size, were not found to be prognostic of PFS.
RChT was well tolerated and could be completed without interruption in most patients. TMZ was generally well tolerated. The most common adverse events among patients who received adjuvant TMZ were fatigue and nausea. Grade III/IV adverse events consisted of grade III thrombocytopenia in 1 patient and grade III fatigue in two patients. Adjuvant TMZ treatment of three patients was discontinued because of thrombocytopenia (n=1), traumatic bone fractures (n=1), or voluntary withdrawal (n=1). Notably, none of the patients who received more than six cycles of adjuvant TMZ showed any toxicity at all. The patient treated with ETMR is still tumor free 6 years after tumor recurrence without major neurocognitive deficits. A substitutional hormone therapy is necessary to ensure mental and physical development.
Our literature review in 2016 indicated 69 reported cases of ETMR, including our case. The mean age at the time of diagnosis was 25.4 months (range: 3-57 months). Survival data were available for 48 children (including our case): the median OS was 13.0 months. Patients who underwent STR or GTR had a significant survival benefit in comparison with patients on whom only biopsy could be performed (14 vs. 6 months, p = 0.006) but there were no major differences between the STR and GTR groups. The children who were irradiated had a significant survival benefit relative to non-irradiated children (16 vs. 11 months, p = 0.029). Our literature search revealed 6 (including our case) unusually long survivors (at least 30 months after diagnosis) with ETMR. The mean age at diagnosis among long survivals was 31.2 months (range 7-48 months). At the time of the report each of the 6 children was free of disease. They were all operated: 2/6 STR and 4/6 GTR. 1 child who did not receive adjuvant therapy was reoperated 11 months after the first surgery because of tumor recurrence and then received combined ChT volumetric measurements is a precise method to detect tumor regression. We observed significant TV shrinkage independently of the applied radiation modality one and two years after RT.
5.2.
Our results demonstrate that RChT after neurosurgery was safe and effective in patients diagnosed with GBM aged ≥60 years. In particular, a significant survival benefit was seen with the administration of maintenance TMZ after surgery and RT. Overall, more aggressive antitumor therapy in selected patients with GBM over 60 years of age was associated with longer survival. Our findings suggest that aggressive treatment for GBM should not be withheld from patients solely because of their advanced age. 5.3.1. ETMR exhibits a highly malignant course, but some case reports provide evidence that long-term disease free survival can be achieved through radical tumor resection, ChT, SCT and RT. CSI is strongly recommended because ETMR shows a high potential of spreading via the CSF. The application of RChT using advanced RT delivery technique can result in a survival benefit, and TMZ might be effective in embryonal brain malignancies and well tolerated by young children. 5.3.2. The conclusions drawn from meta-analyses of reports on benign NC cannot be applied in cases with aggressive behavior. NC patients with potential malignant transformation should be differentiated, and treated accordingly. Apart from histopathological malignant features the correct evaluation of the MIB-1 LI can help in the identification of these patients. In that cases multimodal treatment including CSI should be considered. 15
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